A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3

Background and purpose Peginterferon Lambdawas being developed as an alternative to alfa interferon for the treatment of chronic hepatitis C virus(HCV) infection. We compared peginterferon Lambda-1a plus ribavirin( Lambda/RBV) and Lambda/RBV plus daclatasvir(DCV; pangenotypic NS5Ainhibitor) with peginterferon alfa-2aplus RBV (alfa/RBV) in treatment-naive patients with HCV genotype2 or 3 infection.